<DOC>
	<DOCNO>NCT01263223</DOCNO>
	<brief_summary>The purpose study determine effect LY2216684 heart rate blood pressure research participant MDD treat SSRI ( selective serotonin reuptake inhibitor ) . Information side effect may occur also collect . The duration participation study approximately 24 day include screen visit . This study require 1 clinic confinement 17 days/16 night 1 Follow-up Outpatient Visit . A screen visit require within 30 day prior start study . In period 1 2 , study involve 4 single daily dose 18 mg LY2216684 placebo take 2 tablet mouth . In period 3 , study involve four single daily dose 36 mg LY2216684 placebo take 4 tablet mouth .</brief_summary>
	<brief_title>A Study LY2216684 Major Depressive Disorder Patients Taking Selective Serotonin Reuptake Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<mesh_term>Phenylethyl Alcohol</mesh_term>
	<criteria>Are patient diagnosed MDD stable dose selective serotonin reuptake inhibitor ( SSRI ) least 4 week prior enrollment , determine medical history physical examination . Male patient : Agree use reliable method birth control study 3 month follow last dose study drug . Female patient Are woman childbearing potential test negative pregnancy time enrollment , use reliable method birth control 6 week prior administration study drug , agree use reliable method birth control study 1 month follow last dose study drug ; Women childbearing potential due surgical sterilization ( hysterectomy bilateral oophorectomy tubal ligation ) menopause least 1 year without menses 6 month without menses follicle stimulate hormone ( FSH ) &gt; 40 mIU/mL . Have body mass index ( BMI ) 32.0 kg/m2 . Have normal BP pulse rate ( systolic BP &lt; 140 , diastolic BP &lt; 90 ; supine position stand ) determine investigator . Patients diagnosis hypertension well control stable dose ( least 4 week diuretic , angiotensin convert enzyme [ ACE ] inhibitor , angiotensin 2 receptor inhibitor ) acceptable inclusion study . Allowance specific antihypertensive per investigator 's discretion . Have screen clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator . Have venous access sufficient allow blood sample per protocol . Are reliable willing make available duration study willing follow study procedure . Have give write informed consent approve Lilly institutional review board ( IRB ) govern site . Are currently enrol , discontinue within last 30 day , clinical trial involve investigational drug device offlabel use drug device study drug use study , concurrently enrol type medical research judge scientifically medically compatible study . Have know allergy compound relate LY2216684 . Are persons previously complete withdrawn study study investigate LY2216684 . Have clinically significant abnormality 12lead ECG , opinion investigator , increase risk associate participate study . Have significant history presence cardiovascular ( include dysrhythmias ) , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder , condition capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data . Have unequal BP ( &gt; 20 mm Hg ) leave arm versus right arm ( measure BP cuff ) absent unequal radial pulse either arm . Have history seizure disorder . Regularly use know drug abuse and/or show positive finding urinary drug screening . Show evidence human immunodeficiency virus ( HIV ) and/or positive human HIV antibody . Show evidence hepatitis C and/or positive hepatitis C antibody . Show evidence hepatitis B and/or positive hepatitis B surface antigen . Are woman positive pregnancy test woman lactate . Use overthecounter prescription medication ( stable dos SSRI note ) narrow therapeutic index ( include , limited warfarin clopidogrel ) know effect heart rate ( e.g. , betablockers ) within 14 day prior dose . Use drug substance know strong inducer inhibitor CYP2D6 CYP3A4 within 30 day prior checkin ( study entry ) conduct study . Have donate blood 500 mL within 4 week prior screen . Have average weekly alcohol intake exceed 14 unit per week , unwilling stop alcohol consumption 48 hour prior checkin ( study entry ) completion study ( 1 unit = 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) . Consume 5 cup coffee ( beverage comparable caffeine content ) per day , habitual basis , patient unwilling adhere study caffeine restriction . Patients must adhere smoke restriction Clinical Research Unit ( CRU ) resident CRU . Have consume grapefruit grapefruitcontaining product 7 day prior enrollment unwilling avoid study . Have document suspected history glaucoma . Patients determine unsuitable investigator reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>